Posts

Showing posts with the label Nordic Regulatory Affairs Market Size

Nordic Regulatory Affairs Market Size To Hit USD 272.7 Million By 2028

  San Francisco, 20 April 2021:   The Report  Nordic Regulatory Affairs Market  Size, Share & Trends Analysis Report By Service, By Service Provider, By Company Size, By Category, By Product Stage, By Indication, By End-use, By Country, And Segment Forecasts, 2021 - 2028 The Nordic regulatory affairs market size is expected to reach USD 272.7 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.5% from 2021 to 2028. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market. Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for

Nordic Regulatory Affairs Market Led To A Lucrative Growth With USD 272.7 Million By 2028

  San Francisco, 17 March 2021:   The Report  Nordic Regulatory Affairs Market  Size, Share & Trends Analysis Report By Service, By Service Provider, By Company Size, By Category, By Product Stage, By Indication, By End-use, By Country, And Segment Forecasts, 2021 - 2028 The Nordic regulatory affairs market size is expected to reach USD 272.7 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.5% from 2021 to 2028. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market. Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for